Dental amalgam affects urinary selenium excretion

Selenium may have a protective effect against mercury toxicity. The aim of the present study was to investigate if selenium excretion in urine was affected in persons with dental amalgam fillings. The reason for this study is that dental amalgam is the most important source of inorganic mercury exposure in the general population, although the potential toxic effects of this exposure remain a subject for debate. The chelating agent 2,3 dimercaptopropane-1-sulfonate (DMPS) was injected intravenously (2 mg/kg) to provoke metal excretion. Urine samples were subsequently collected at intervals over a 24-h period. Selenium concentration was determined by hydride-generation atomic absorption spectrometry. The study was comprised of 20 persons who claimed symptoms from dental amalgam and 21 healthy persons with amalgam fillings. There were two control groups without amalgam. One control group had amalgam replaced because of concern about illness resulting from mercury release (n=20), whereas the other control group never had amalgam (n=19). Individuals with amalgam excreted less selenium (36.4 μg, median value) over 24 hours than those without amalgam (47.5 μg) (p=0.016). There was no difference in selenium excretion between groups with (42.4 μg) and without (39.4 μg) amalgam-related symptoms (p=0.15). The findings indicate that individuals exposed to low levels of elemental mercury from dental amalgam excrete less selenium to urine than unexposed individuals.     

A sensitive and specific enzyme immunoassay for the detection of methyl ether derivatives of cyclomaltoheptaose

We have raised antibodies against two methylated derivatives of beta-CD, heptakis(2,6-di-O-methyl)cyclomaltoheptaose (Dimeb) and heptakis(2,3,6-tri-O-methyl)cyclomaltoheptaose (Trimeb). These antibodies were used to develop two specific and sensitive enzyme immunoassays, presenting a detection limit close to 500 and 30 pg/mL for Trimeb and Dimeb, respectively. Cross reactivities of different linear and cyclic maltooligosaccharides were investigated, demonstrating a high specificity against the structural features of the secondary hydroxyls rim. Several commercial Dimeb samples, containing different mixtures of partially methylated beta-cyclodextrin derivatives including RAMEB, which contains only a few amount of pure Dimeb, could be easily evaluated by the Dimeb immunoassay. Both of these assays have been shown to allow accurate measurement in plasma and urine, thus appearing as useful tools for further applications in biological material.     

Creatine Kinase Activity from Rat Brain Is Inhibited by Branched-Chain Amino Acids in Vitro

Maple syrup urine disease (MSUD) is an inherited metabolic disorder biochemically characterized by the accumulation of branched-chain amino acids (BCAAs) and their branched-chain keto acids (BCKAs) in blood and other tissues. Neurological dysfunction is usually present in the affected patients, but the mechanisms of brain damage in this disease are not fully understood. Considering that brain energy metabolism seems to be altered in MSUD, the main objective of this study was to investigate the in vitro effect of BCAAs and BCKAs on creatine kinase activity, a key enzyme of energy homeostasis, in brain cortex of young rats. BCAAs, but not their BCKAs, significantly inhibited creatine kinase activity at concentrations similar to those found in the plasma of MSUD patients (0.5–5 mM). Considering the crucial role creatine kinase plays in energy homeostasis in brain, if this effect also occurs in the brain of MSUD patients, it is possible that inhibition of this enzyme activity may contribute to the brain damage found in this disease.     

Determination of 5-methyltetrahydrofolate (13C-labeled and unlabeled) in human plasma and urine by combined liquid chromatography mass spectrometry

The association of folates with the prevention of neural tube defects and reduced risk of other chronic diseases has stimulated interest in the development of techniques for the study of their bioavailability in humans. Stable isotope protocols differentiate between oral and/or intravenous test doses of folate and natural levels of folate already present in the body. An liquid chromatography/mass spectrometry (LC/MS) procedure is described that has been validated for the determination of [13C]5-methyltetrahydropteroyl monoglutamic acid ([13C]5-CH3H4PteGlu) in plasma and urine, following oral dosing of volunteers with different labeled folates. Folate binding protein affinity columns were used for sample purification prior to LC/MS determination. Chromatographic separation was achieved using a Superspher 100RP18 (4 microm) column and mobile phase of 0.1 mol/L acetic acid (pH 3.3):acetonitrile (90:10; 250 microL/min). Selected ion monitoring was conducted on the [M-H](-) ion: m/z 458 and 459 for analyzing 5-CH3H4PteGlu; m/z 464 [M+6-H](-) to determine 5-CH3H4PteGlu derived from the label dose; m/z 444 for analysis of 2H4PteGlu internal standard, and m/z 446 and 478 to confirm that there was no direct absorption of unmetabolized compounds. Calibration was linear over the range 0-9 x 10(-9) mol/L; the limits of detection and quantification were 0.2 x 10(-9) and 0.55 x 10(-9) mol/L, respectively. The mean coefficient of variation of the ratios (m/z 463/458) was 7.4%. The method has potential applications for other key folates involved in one-carbon metabolism.     

Enhanced activity of serum and urinary hyaluronidases in streptozotocin-induced diabetic Wistar and GK rats

Using streptozotocin-induced diabetic Wistar and GK rats as models of type 1 and type 2 diabetes, respectively, we investigated the changes in serum and urinary hyaluronidase activity with the pathological progress. The serum hyaluronidase levels of streptozotocin-induced rats started to increase on the third day after injection and thereafter maintained approximately threefold higher levels compared with control rats; those of GK rats were already higher ( approximately twofold) from the beginning of the experiment. The increases of serum hyaluronidase activity in both diabetic rats were similar to those of blood glucose level, indicating that diabetes mellitus was accompanied by enhanced activity of circulating hyaluronidase from the early phase of its development. In zymography, every serum from diabetic and control rats gave two hyaluronidase isomers, a major 73-kDa band (Hyal-1 type) and a minor 132-kDa band, suggesting that the increases in serum hyaluronidase activity were not due to the appearance of novel isomers. The hyaluronidase activity in 24-h urine of streptozotocin-induced rats was 3-, 7-, and 11-fold higher at the 8th, 15th, and 18th week than that of control rats, respectively, and the urinary hyaluronidase activity of GK rats was not significantly different from controls. There was a good correlation between the urinary hyaluronidase activity and the albumin excretion. Thus the increase in urinary hyaluronidase activity may reflect enhanced glomerular permeability in streptozotocin-induced diabetic rats and may be a useful marker for diabetic nephropathy. Relative resistance to SDS-denaturation in zymography of rat serum and urinary hyaluronidases compared with human serum hyaluronidase are also shown.     

Urinary selenium excretion in patients with cervical uterine cancer

In this work, we report on a relationship between urinary selenium and the development of cervical uterine cancer. A simple chemical method was developed to concentrate trace amounts of selenium from relatively large urine samples by use of small activated carbon filters. When these filters are irradiated with thermal neutrons, selenium can be determined either by ^77mSe (t _1/2=17.5 s) or ⁷⁵Se (t _1/2=120 d). In this article, we report the results for 82 urine samples from women with cervical uterine cancer in several stages of development and from healthy controls. These results show a statistically significant increase of selenium excretion in cancer patients as compared to controls. Urinary selenium excretion is highest for patients in the intermediate stages of the disease.     

大鼠、豚鼠和金黄地鼠的尿液蛋白质组比较

生物标志物是指与生理或病理变化相关的可监测的变化。尿液作为机体的一种排泄物,不受稳态机制的调节,可以反映机体的多种变化。动物模型可以模拟人类疾病过程,监测疾病的变化,并为早期诊断提供线索。大鼠作为常用的模型动物并非所有疾病的优势模型动物,因此比较大鼠与其他动物的尿液蛋白质组,从而为其他疾病选择优势模型动物提供线索。文中通过膜上酶切切成肽段再通过液相色谱与串联质谱偶联技术(LC-MS/MS)分析肽段信息,比较大鼠、豚鼠和金黄地鼠的尿液蛋白,结果显示3种鼠的尿蛋白数量不同,在机体不同系统中表达情况不同,参与的生物功能也不同。这为不同疾病选择不同的优势模型动物提供了依据。     

脊髓性肌萎缩症患者尿液细胞模型的建立

脊髓性肌萎缩症(Spinal muscular atrophy, SMA)大多数在儿童或婴幼儿期发病,表现为进行性、对称性的肢体无力和肌肉萎缩,迄今尚无有效的治疗方法,是婴幼儿最常见的致死性遗传病之一。患者来源的细胞系是该病研究的重要工具,但依赖于肌肉或皮肤活检等创伤性手术的成纤维细胞培养较难被患者及家属接受。文章收集SMA患者及健康对照的新鲜尿液,进行离心、尿液沉渣培养,观察尿液细胞的生长状况,用酶联免疫吸附实验(Enzyme-linked immunosorbent assay,ELISA)分析患者尿液细胞中SMN(Survival of motor neuron)蛋白的表达量,应用免疫荧光染色观察SMN蛋白在细胞内的定位。共建立了11例SMA患者和14例健康对照的尿液细胞系,尿液细胞体外增殖旺盛,细胞形态及生长速度较稳定。患者来源的尿液细胞SMN1(Survival of motor neuron 1) 基因缺失突变、SMN蛋白表达量降低,荧光染色提示SMN蛋白在胞浆和胞核中均有定位。尿液细胞培养步骤简单、无创伤性、患儿及其家属的依从性好,是获取和保存病人来源标本的有效方法,在脊髓性肌萎缩症发病机制研究和临床应用方面具有较好的应用价值。     

实时荧光核酸恒温扩增技术和液体培养法检测解脲脲原体的比较

目的:对实时荧光核酸恒温扩增技术(SAT)和液体培养法检测解脲脲体(UU)的结果进行评估,以选择更为快速、准确、实用的临床检测方法.方法:共采集180例疑似泌尿生殖道感染患者的尿液及2份拭子样本,一份拭子样本用液体培养,另一份拭子和尿液样本用 SAT 检测.结果:液体培养和尿液 SAT 检测阳性率均为61.1%,拭子SAT 检测阳性率为63.3%,其中16例拭子培养和拭子 SAT 检测结果不一致,18例拭子培养和尿液 SAT 结果不一致,但与拭子培养比较,拭子和尿液 SAT 结果均无统计学意义(P>0.05,kappa>0.75).结论:SAT 检测 UU 可以尿液为样本,检测效能与液体培养和拭子 SAT 基本相当,但尿液 SAT 法取样方便,检测快速,适临床实验室对 UU 的检测.     

A high-throughput screening (HTS) immunochemical method for the analysis of stanozolol metabolites in cattle urine samples

A high-throughput immunosorbent solid-phase extraction (HTS-IS-SPE) procedure coupled to enzyme-linked immunosorbent assay (ELISA) has been established for the analysis of stanozolol (St) and its main metabolite in cattle, 16β-hydroxy-stanozolol (16βOH-St), in cow urine samples. The chemical structure of the immunizing hapten 2′H-androst-2-eno[3,2-c]-pyrazol-17-hemiglutarate 5 (hapten A) has been designed to accomplish simultaneous detection of St and 16βOH-St. The antibodies obtained have been used to establish a microplate ELISA method able to detect these metabolites with IC₅₀ values of 0.57 μg L⁻¹ and 1.46 μg L⁻¹, respectively in PBST. Immunosorbents prepared by covalently attaching the antibodies to Sepharose, efficiently removed the matrix interferences caused by the cattle urine samples. Moreover, St and 16βOH-St were efficiently extracted from urine samples as demonstrated by LC–MS/MS analysis. The immunosorbents are filled on small mini-columns arranges on a 96-SPE-setup compatible with the microplate based ELISA methods. Samples and standards can be run in parallel which increment considerably the speed of the screening method. The recovery values of the whole HTS-IS-SPE-ELISA procedure has found to be 112 ± 10% and St can be detected in hydrolyzed urine samples with LOD of 1.26 ± 0.46 μg L⁻¹ using just 1 mL of sample. As proof-of-concept the urinary excretion profile of St treated animals has been investigated by analyzing individual sampling points. Results from pooled urine samples have also been compared with the results obtained by GC–MS analysis demonstrating the StIR equiv. measured with the HTS-IS-SPE-ELISA protocol are in accordance with the St and 16βOH-St levels found with the chromatographic method. The analytical procedure is rapid, effective and the detectability achieved is below the MPRL (minimum performance required levels) recommended by CRL (Community Reference Laboratory) to the European Community.